$2.04 +0.07 (3.55%)

Invivyd, Inc. Common Stock (IVVD)

Invivyd, Inc. (IVVD) is a biotechnology company focused on developing innovative therapeutics and vaccines for infectious diseases, with an emphasis on viral pathogens. The company utilizes antibody-based and other advanced technologies to create treatments aimed at preventing and combating infectious illnesses.

🚫 Invivyd, Inc. Common Stock does not pay dividends

Company News

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
GlobeNewswire Inc. • Invivyd, Inc. • August 22, 2025

Invivyd completed a public offering of 89,234,480 shares and pre-funded warrants, raising approximately $57.5 million to fund clinical trials, research and development, and corporate purposes.

JIII
Invivyd Revenue Jumps 413 Percent in Q2
The Motley Fool • Jesterai • August 14, 2025

Biotech firm Invivyd reported Q2 2025 earnings with 413% revenue growth to $11.8 million, falling short of analyst expectations. The company continues developing COVID-19 monoclonal antibodies while exploring new viral disease treatments.

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Benzinga • Avi Kapoor • April 5, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura Sushi USA, Inc. (NASDAQ: KRUS) climbed 6% to $110.11 in pre-market trading following the release of second-quarter results. The company reported quarterly losses of 9 cents per share, missing the analyst estimate of losses of ...

CNKKRUSDNUTCRBUVTYXFRGE
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
Zacks Investment Research • Zacks Equity Research • January 12, 2024

Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.